We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Draft Guidance Lays Out FDA Thinking on AML Clinical Studies
Draft Guidance Lays Out FDA Thinking on AML Clinical Studies
The FDA is willing to consider a range of clinical trial designs and various endpoints for new drugs or biologics intended to treat acute myeloid leukemia (AML), according to a new draft guidance.